Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

976
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
976

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026
Same author

Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics.

PloS one·2026
Same author

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.

Oncoimmunology·2026
Same author

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Journal for immunotherapy of cancer·2026
Same author

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Future oncology (London, England)·2026

Related Experiment Video

Updated: Jan 18, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?

Lucía Ceniceros1, Manuel de La Torre2, Ana Landa Magdalena1

  • 1Liver Unit, Cancer Center Clinica Universidad de Navarra (CCUN), Program in Solid Tumors (CIMA), Universidad de Navarra, Clínica Universidad de Navarra, 31008 Pamplona, Spain.

Cancers
|September 13, 2025
PubMed
Summary
This summary is machine-generated.

Immune-checkpoint inhibitors (ICI) show modest effects in biliary tract cancer (BTC). Research is exploring novel combinations and patient selection strategies to improve outcomes for this aggressive malignancy.

Keywords:
biliary tract cancerimmune-checkpoint inhibitorstreatment outcome

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

Related Experiment Videos

Last Updated: Jan 18, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Biology

Background:

  • Biliary tract cancer (BTC) is a rare, aggressive malignancy with significant tumor and immune microenvironment heterogeneity.
  • Most patients present with advanced disease, facing limited curative treatment options.
  • Current immune-checkpoint inhibitors (ICI) offer modest benefits for BTC patients.

Purpose of the Study:

  • To review the current role and evolving landscape of ICIs in biliary tract cancer.
  • To discuss how tumor heterogeneity impacts treatment response to immunotherapies.
  • To explore future strategies for optimizing patient selection for BTC treatment.

Main Methods:

  • This review synthesizes current literature on immune-checkpoint inhibitors in BTC.
  • It analyzes the impact of tumor biology and immune microenvironment heterogeneity.
  • It examines ongoing research into combination therapies and patient stratification.

Main Results:

  • While ICIs have transformed other cancers, their efficacy in BTC remains limited.
  • Combination therapies show incremental survival improvements in advanced BTC.
  • Tumor heterogeneity presents a significant challenge for effective immunotherapy.

Conclusions:

  • Optimizing ICI therapy in BTC requires addressing tumor heterogeneity.
  • Future research should focus on novel combination strategies and precise patient selection.
  • Improving therapeutic outcomes for advanced BTC remains a critical unmet need.